Efgartigimod alfa

Therapeutic indications

Efgartigimod alfa is indicated for:

Generalized myasthenia gravis in acetylcholine receptor antibody-positive patients

Population group: only adults (18 years old or older)

Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg/kg once weekly for 4 weeks or 1,200 mg per infusion for patients weighing ≥120 kg

Contraindications

Efgartigimod alfa is contraindicated in the following cases:

Vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.